Vanguard Group Inc Chembio Diagnostics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.2 - $0.33 $108 - $179	-544 Reduced 0.03%	1,561,470 $343,000
Q3 2022 Nov 14, 2022	BUY	$0.35 - $1.1 $160,107 - $503,195	457,450 Added 41.41%	1,562,014 $564,000
Q1 2022 May 13, 2022	SELL	$0.66 - $1.23 $198,805 - $370,501	-301,221 Reduced 21.43%	1,104,564 $906,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $2.55 $553,819 - $1.3 Million	508,091 Added 56.6%	1,405,785 $1.6 Million
Q3 2021 Nov 12, 2021	BUY	$2.06 - $5.34 $87,444 - $226,677	42,449 Added 4.96%	897,694 $2.25 Million
Q2 2021 Aug 13, 2021	BUY	$2.88 - $5.64 $2.46 Million - $4.82 Million	855,245 New	855,245 $2.54 Million

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.